AI assistant
AGENUS INC — Director's Dealing 2011
Apr 28, 2011
34023_dirs_2011-04-28_549ef312-52b2-4bfc-bac0-d5c17b4c8712.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: AGENUS INC (AGEN)
CIK: 0001098972
Period of Report: 2011-04-26
Reporting Person: ARMEN GARO H (Chairman & CEO)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2011-04-26 | Common Stock | A | 8333 | $0.92 | Acquired | 2957344 | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 5139291 | Indirect |
Footnotes
F1: Represents settlement of restricted stock awarded January 26, 2010.
F2: Dr. Armen is trustee and has investment authority for the Garo Armen 2009 2 year GRAT and the Garo Armen 4 Year GRAT, each holding 1,271,102 and 2,336,246 shares of Agenus Inc. common stock, respectively. Dr. Armen disclaims beneficial ownership therein. Dr. Armen is the Gerneal Partner of Armen Partners LP. As of the date of this report Armen Partners owns a total of 1,507,667 shares of Agenus Inc. common stock. Dr. Armen is also CEO, Chairman of the Board of Managers and a member of Antigenics Holdings LLC ("Holdings") which as of the date of this report owns 24,276 shares of Agenus Inc. common stock. Dr. Armen has a pecuniary interest in only a portion of the shares held by Armen Partners and Holdings, and disclaims beneficial ownership except to the extent of his pecuniary interest therein.